Latus Bio secures $97m in funding to boost gene therapy access
Pharmaceutical Business Review
The financing includes a $43m extension led by 8VC, with participation from existing investors BioAdvance, Benjamin Franklin Technology Partners, DCVC Bio, Gaingels, Hatch BioFund and Modi Ventures.
pharminent
May 5, 2026 (Last updated: May 5, 2026)
Pharmaceutical Business Review
The financing includes a $43m extension led by 8VC, with participation from existing investors BioAdvance, Benjamin Franklin Technology Partners, DCVC Bio, Gaingels, Hatch BioFund and Modi Ventures.
